189 related articles for article (PubMed ID: 34044110)
21. Small cationic DDA:TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses.
Milicic A; Kaur R; Reyes-Sandoval A; Tang CK; Honeycutt J; Perrie Y; Hill AV
PLoS One; 2012; 7(3):e34255. PubMed ID: 22470545
[TBL] [Abstract][Full Text] [Related]
22. The surface charge of liposomal adjuvants is decisive for their interactions with the Calu-3 and A549 airway epithelial cell culture models.
Ingvarsson PT; Rasmussen IS; Viaene M; Irlik PJ; Nielsen HM; Foged C
Eur J Pharm Biopharm; 2014 Aug; 87(3):480-8. PubMed ID: 24726978
[TBL] [Abstract][Full Text] [Related]
23. Effect of incorporating cholesterol into DDA:TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses.
Kaur R; Henriksen-Lacey M; Wilkhu J; Devitt A; Christensen D; Perrie Y
Mol Pharm; 2014 Jan; 11(1):197-207. PubMed ID: 24171445
[TBL] [Abstract][Full Text] [Related]
24. Engineering of an inhalable DDA/TDB liposomal adjuvant: a quality-by-design approach towards optimization of the spray drying process.
Ingvarsson PT; Yang M; Mulvad H; Nielsen HM; Rantanen J; Foged C
Pharm Res; 2013 Nov; 30(11):2772-84. PubMed ID: 23794038
[TBL] [Abstract][Full Text] [Related]
25. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog.
Christensen D; Henriksen-Lacey M; Kamath AT; Lindenstrøm T; Korsholm KS; Christensen JP; Rochat AF; Lambert PH; Andersen P; Siegrist CA; Perrie Y; Agger EM
J Control Release; 2012 Jun; 160(3):468-76. PubMed ID: 22709414
[TBL] [Abstract][Full Text] [Related]
26. Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: A quality-by-design approach.
Rose F; Wern JE; Ingvarsson PT; van de Weert M; Andersen P; Follmann F; Foged C
J Control Release; 2015 Jul; 210():48-57. PubMed ID: 25957906
[TBL] [Abstract][Full Text] [Related]
27. Cationic DDA/TDB liposome as a mucosal vaccine adjuvant for uptake by dendritic cells in vitro induces potent humoural immunity.
Qu W; Li N; Yu R; Zuo W; Fu T; Fei W; Hou Y; Liu Y; Yang J
Artif Cells Nanomed Biotechnol; 2018; 46(sup1):852-860. PubMed ID: 29447484
[TBL] [Abstract][Full Text] [Related]
28. Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C).
Schmidt ST; Pedersen GK; Neustrup MA; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Front Immunol; 2018; 9():898. PubMed ID: 29760705
[TBL] [Abstract][Full Text] [Related]
29. Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant.
Korsholm KS; Hansen J; Karlsen K; Filskov J; Mikkelsen M; Lindenstrøm T; Schmidt ST; Andersen P; Christensen D
Vaccine; 2014 Jun; 32(31):3927-35. PubMed ID: 24877765
[TBL] [Abstract][Full Text] [Related]
30. Influence of trehalose 6,6'-diester (TDX) chain length on the physicochemical and immunopotentiating properties of DDA/TDX liposomes.
Kallerup RS; Madsen CM; Schiøth ML; Franzyk H; Rose F; Christensen D; Korsholm KS; Foged C
Eur J Pharm Biopharm; 2015 Feb; 90():80-9. PubMed ID: 25445301
[TBL] [Abstract][Full Text] [Related]
31. Immunocorrelates of CAF family adjuvants.
Pedersen GK; Andersen P; Christensen D
Semin Immunol; 2018 Oct; 39():4-13. PubMed ID: 30396811
[TBL] [Abstract][Full Text] [Related]
32. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.
Agger EM; Rosenkrands I; Hansen J; Brahimi K; Vandahl BS; Aagaard C; Werninghaus K; Kirschning C; Lang R; Christensen D; Theisen M; Follmann F; Andersen P
PLoS One; 2008 Sep; 3(9):e3116. PubMed ID: 18776936
[TBL] [Abstract][Full Text] [Related]
33. Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response.
Kaur R; Bramwell VW; Kirby DJ; Perrie Y
J Control Release; 2012 Dec; 164(3):331-7. PubMed ID: 22800572
[TBL] [Abstract][Full Text] [Related]
34. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen.
Henriksen-Lacey M; Bramwell VW; Christensen D; Agger EM; Andersen P; Perrie Y
J Control Release; 2010 Mar; 142(2):180-6. PubMed ID: 19874860
[TBL] [Abstract][Full Text] [Related]
35. Scale-Independent Microfluidic Production of Cationic Liposomal Adjuvants and Development of Enhanced Lymphatic Targeting Strategies.
Roces CB; Khadke S; Christensen D; Perrie Y
Mol Pharm; 2019 Oct; 16(10):4372-4386. PubMed ID: 31437396
[TBL] [Abstract][Full Text] [Related]
36. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production.
Henriksen-Lacey M; Devitt A; Perrie Y
J Control Release; 2011 Sep; 154(2):131-7. PubMed ID: 21640145
[TBL] [Abstract][Full Text] [Related]
37. Potentiation of Th1-Type Immune Responses to
Ko A; Wui SR; Ryu JI; Lee YJ; Hien DTT; Rhee I; Shin SJ; Park SA; Kim KS; Cho YJ; Lee NG
J Microbiol Biotechnol; 2018 Jan; 28(1):136-144. PubMed ID: 29081214
[TBL] [Abstract][Full Text] [Related]
38. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: Role of lymphatic trafficking and biodistribution.
Zhuang Y; Ma Y; Wang C; Hai L; Yan C; Zhang Y; Liu F; Cai L
J Control Release; 2012 Apr; 159(1):135-42. PubMed ID: 22226776
[TBL] [Abstract][Full Text] [Related]
39. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants.
Romero Méndez IZ; Shi Y; HogenEsch H; Hem SL
Vaccine; 2007 Jan; 25(5):825-33. PubMed ID: 17014935
[TBL] [Abstract][Full Text] [Related]
40. A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522.
Rose F; Wern JE; Gavins F; Andersen P; Follmann F; Foged C
J Control Release; 2018 Feb; 271():88-97. PubMed ID: 29217176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]